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ABSTRACT
Introduction A growing body of evidence suggests
even small rises in serum creatinine (SCr) are of
considerable clinical relevance. Given that participants
in endurance events are exposed to potential (repeated)
renal insults, a systematic review was undertaken to
collate current evidence for acute kidney injury (AKI),
complicating such events.
Methods A systematic review of studies and case
reports meeting inclusion criteria on Medline and
EMBASE (inception to October 2015). Included: studies
with markers of renal function before and after
endurance or ultraendurance events; case reports of
severe AKI. Two reviewers assessed risk of bias using
the Newcastle-Ottawa scale.
Results Eleven case report publications (n=27
individuals) of severe AKI, were retrieved, with risk
factors including systemic illness or nephrotoxic
medications usually identified. From 30 studies of
endurance and ultraendurance events, mean rise in SCr
was 29 (±12.3) mmol/L after marathon or
ultramarathon (17 studies, n=568 participants) events.
Where follow-up tests were conducted, SCr returned to
baseline within 48 hours. Rises in biomarkers suggest
potential parenchymal insult, rather than simply muscle
breakdown. However, evidence of long-term
deleterious effects is lacking.
Conclusions Raised levels of SCr are reported
immediately after endurance events. It is not clear
whether this is either clinically significant, or if
repeated participation predisposes to long-term
sequelae. The aetiology of severe exercise-associated
AKI is usually multifactorial, with risk factors generally
identified in the rare cases reported. On-site
biochemistry, urine analysis and biomarkers of AKI
may help identify collapsed runners who are at
significant short-term risk and allow suitable follow-up.
INTRODUCTION
Endurance events continue to increase in
popularity. For example, marathon partici-
pation in the USA has risen from 25 000 in
1976 to over half a million in 2011.1 Partici-
pation in ultramarathons (a running event
involving a distance longer than the tradi-
tional marathon length)2 is also rapidly
growing. Although individuals who exercise
regularly have lower rates of disability and a
mean life expectancy some 6 years longer
than that of their less active contemporaries,
there remain some concerns regarding
potential adverse sequelae.3–5 Although
sudden death among athletes attracts much
publicity, it is rare and often due to a pre-
existing cardiomyopathy.6–9 More
commonly, less severe organ damage may
occur during strenuous exercise, which, if
repeated over time, could have long-term
significance, including renal damage, as
evidenced by animal studies10 and human
studies investigating cardiac imaging and
enzyme markers.11–19 Though long-term
evidence of harm remains scarce, recent
studies have suggested an attenuation of the
benefits of exercise, among those
performing the most strenuous exercise,
with a J-shaped or U-shaped association
between all-cause mortality and running
dose.20–22
Quantifying renal damage and defining
renal failure has, until recently, suffered
What are the new findings
" Twenty-seven cases of acute kidney injury (AKI)
requiring hospital treatment after an endurance
or ultraendurance event have been reported, with
rhabdomyolysis often associated alongside at
least one other identifiable risk factor.
" Across 21 studies (n=800), including half-mara-
thons, where pre-event and postevent serum
creatinine (SCr) levels were available, mean SCr
increase was 25.7 (±11.6) Gmol/L.
" Of the 17 marathons or ultramarathons studied
(n=568), mean SCr increase was 29 (±12.3)
Gmol/L.
" Non-steroidal anti-inflammatory agents appear to
be a significant risk factor for AKI, though few
studies in this area have been published.
" Use of renal biomarkers is of growing interest
and in collapsed runners, may help identify those
at high risk of significant AKI.
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from a lack of consensus definition. However this has
been addressed, in part, by the adoption of the
concept of acute kidney injury (AKI) which classifies
renal injury on the basis of changes in measured serum
creatinine (SCr) compared with baseline values and/or
changes in monitored urine output (see Appendix for
AKI definitions).23 24 This has allowed classification of
patients, particularly in acute settings such as the crit-
ical care environment, allowing comparison between
groups, as well as defining renal injury, which may not
progress to renal failure requiring extracorporeal
support. Of particular relevance is the observation that
what was previously viewed as relatively trivial increases
in SCr, carries an increase in acute mortality. It is now
clear that renal injury, as defined by AKI, puts patients
at longer-term risks of both morbidity and mortality.25–
27
The earliest studies reporting urinary changes on
extreme exercise coincided with the seminal work by
Bywaters and Beall describing the biochemical and
histopathological features of crush injury observed in
air raid victims during World War II which we now
describe as rhabdomyolysis.28 The first documented
study in athletes was in 1941 and described myoglobi-
nuria, haematuria and albuminuria in marathon
runners with the first case reports of acute renal failure
complicating any sporting event reported in the
1960s.29 30 Within the clinical arena there are
numerous potential specific causes of AKI but a
number of factors alone, or in combination, may exac-
erbate the condition. These include volume depletion
secondary to inadequate fluid intake and excessive
losses, rhabdomyolysis and the use of drugs such as
non-steroidal anti-inflammatory drugs (NSAIDs). It
follows that these factors may be common to individ-
uals competing in endurance events with the further
potential complications of climate and exercise-associ-
ated heat stroke (EHS).31–35 Therefore, AKI may be a
more common complication of endurance events than
anticipated. While this may seem a relatively harmless
‘side-effect’ of endurance events, there is now a consider-
able body of evidence that points to the fact that an
episode of AKI complicating critical illness, for
example, carries a significant risk of longer-term
mortality and morbidity. Could this observation be
relevant to those exhibiting an SCr rise after endur-
ance events?
Research questions
To systematically review the frequency of AKI) associ-
ated with endurance (and ultraendurance) events; to
quantify changes in SCr as a marker of renal dysfunc-
tion in endurance event studies recording values pre-
event and postevent. Furthermore, the review will
explore mechanisms of renal dysfunction due to exer-
cise-associated rhabdomyolysis and use of NSAIDs;
finally future studies, including the use of renal
biomarkers, will be addressed.
Rationale and objectives
Endurance event participation is increasing and
emerging evidence suggests extreme exercise could
potentially attenuate some of the benefits seen with
regular exercise. AKI is an independent contributor to
mortality in a large number of clinical settings. There
have been case reports of significant AKI requiring
hospital care following endurance events and also
prospectively studied markers of renal dysfunction
following endurance events, but to date, there has been
no systematic review of this field. Thus, the rationale
for this review was to collate all empirical evidence for
AKI in endurance (and ultraendurance) events, fitting
the prespecified eligibility criteria for inclusion, to
answer the research questions. Explicit, systematic
methods were selected with a view to minimising bias
and provide reliable findings from which conclusions
can be drawn.36 37
METHODS
Inclusion criteria
Adult human studies in the English language in peer-
reviewed journals, of endurance or ultraendurance
events, examining markers of renal function; to quan-
tify a change in SCr, studies would be included where
an SCr value pre-event and immediately post the event
was reported, though studies without both values would
also be reported; case report studies of participants
with AKI requiring hospitalisation following an endur-
ance event.
Exclusion criteria
Research involving paediatric patients (<18 years old)
and non-human studies; studies involving events not
considered endurance (eg, <1hour), such as track and
field or football.
Identification, screening, risk of bias
We searched Medline and EMBASE for English
language articles from inception to October 2015 with
the text words and related Medical Subject Headings
terms: ‘AKI,’ ‘acute kidney injury,’ ‘Acute renal failure,’
‘Renal’ and ‘Marathon’ or ‘Endurance events’ as the
initial set of search terms; to ensure a comprehensive
literature search, reference lists were examined from
retrieved articles (see Appendix for search string and
PRISMA flow diagram). Titles and abstracts were
screened and full articles reviewed if thought to be
eligible for inclusion. Data extraction (using a
pretested form), study design and quality
were performed by two investigators. Discrepancies in
any data extraction were discussed and assessment of a
third reviewer was sought for resolution. Two reviewers
assessed the risk of bias of each study using the
Newcastle-Ottawa Scale.38 This scale awards a
maximum of nine stars across three domains (selection,
comparability of cohorts on the basis of the design and
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analysis, and outcome assessment). Studies assigned at
least seven stars were deemed to be of good quality.39
For analysis of the magnitude of change in SCr we
included observational studies in adults in which renal
function was measured before and within hours after
an endurance or ultraendurance event. Case reports of
significant renal dysfunction requiring medical atten-
tion were included where the primary diagnosis was
AKI.
Data extraction
Year of publication, data collection methods (retrospec-
tive or prospective), event (such as a marathon) setting
(country or countries), number included, primary
outcome, pre-SCr and post-SCr (where available),
urine analysis, biomarkers, creatine kinase (CK) in the
case reports of severe AKI; number who collapsed; and
use of NSAIDs. Eleven case report studies reported a
total of 27 cases of AKI. An additional 30 studies
assessing markers of renal function including SCr
changes, urine analysis and biomarkers (total number
of subjects 1724) following endurance or ultraendur-
ance events were found, of which 21 reported pre-
event and postevent SCr levels.
RESULTS
In 11 case report publications, 27 cases of AKI
following endurance events were described (table 1).
Of the events, five were marathons33 40–44 and six
ultramarathons.30 31 45–47 Eight participants had
collapsed during the event. The majority (21/27)
presented to medical attention in a delayed fashion—
sometimes over a week after the event. In two-thirds of
cases (18/27), a history of NSAID before and/or during
the event was elicited. Other risk factors included
recent illness and vomiting during the events. Fifteen
cases required temporary dialysis. A renal biopsy was
performed on only four occasions, with features of
acute tubular necrosis (ATN) in all the biopsies,
suggesting an ischaemic aetiology. A diagnosis of rhab-
domyolysis was made, or presumed, in 85% (n=23) of
the cases. Where reported, follow-up renal function was
reported to be normal, with no requirement for long-
term renal replacement therapy.
A total of 30 studies (n=1724 participants) on renal
function in endurance events were identified (table 2).
These include 13 marathons,35 48–59 10 ultramara-
thons,60–69 2 half-marathons,70 71 an Ironman,72 a 24-
hour marathon relay,73 a 60-km mountain run74 and 2
ultramarathon cycle races.75 76 Of 21 foot race events
(n=800 participants) reporting pre-event and poste-
vent SCr levels, 17 were studies of marathons or
ultramarathons (n=568 participants). For risk of bias,
26 of the studies were deemed of good quality with a
Newcastle-Ottawa Score of at least seven stars (see
supplementary table for full details).
Creatinine production and clearance
A proportion of the SCr rise observed on extreme
exercise reflects increases in muscle breakdown, with
an enhanced solute load, rather than a fall in glomer-
ular filtration rate (GFR).60 Hence the use of SCr to
estimate GFR (eGFR) under conditions of extreme
exercise should be avoided. Interestingly, a study on
six marathon runners demonstrated that on the 1st day
after the race, creatinine clearance actually increased,
peaking on day 3 with increased urine flow rates on all
5 days postrace.35 This reflects the concept of
augmented renal clearance, which is in fact a normal
response to increased tubular flow. Rates of excretion
and production of creatinine were closely matched on
all study days.35 These results are in contrast to a study
which showed no change in creatinine clearance,
although inulin clearance reduced by 50%60 and
further studies in ultramarathon cyclists where a
decline in creatinine clearance of 18–25% was
observed.75 76 Mean fractional sodium and uric acid
excretion also fell, which may indicate reduced renal
perfusion, and SCr rose by 20–36%, returning to
normal at 24 hours.
Rises in SCr
Across 21 studies (n=800) where pre-event and post-
event SCr levels were available, mean SCr increase was
25.7 (±11.6) mmol/L. Of the 17 marathons or ultramar-
athons described (n=568), mean SCr increase was 29
(±12.3) mmol/L, above the threshold for AKI stage 1.24
Though most studies demonstrated an increase in SCr
immediately following the event, in the 13 studies
reporting recovery of function, as described by changes
in SCr, all had returned to baseline or were improving
within 48 hours (table 2). Studies involving half-mara-
thons reported smaller increases in SCr levels, with
eGFR recovering within 6 hours in one study.70 In two
recent extended ultraendurance races over weeks to
months, no contestants developed AKI, despite signifi-
cant rises in CK, suggesting repetitive, relatively lower
intensity exercise, despite the large total distance
covered, may mean that cumulative damage does not
occur in these events.77 78 A recent study by Lipman
et al66 also supports this, documenting rises in SCr,
with 45–67%meeting RIFLE criteria ‘Risk’ and 7–13%
‘Injury’ (see Appendix for RIFLE criteria) between
stages of a multistage ultramarathon race, but found a
rapid reduction back to baseline prior to the following
stage. Christensen et al68 investigated renal function up
to 48hours following a 78-km ultramarathon at
moderate altitude (~2400 m) by 10 runners from the
Mexican Tarahumara tribe, who have maintained the
once widespread tradition of ultradistance running,
from a young age. The authors found immediate post-
race SCr was not significantly elevated, though an
increase of 25% was noted by 6 hours, with a subse-
quent fall-back to baseline at 48 hours. Follow-up for
the 30 studies did not extend beyond more than a few
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days, thus conclusions around the effects of recurrent
participation in such events cannot be made.
Studies examining the use of NSAIDs
In the studies where NSAID use was reported, 23%
(n=312/1359) of participants admitted to NSAID
usage. Two studies, one of marathon runners53 and
another of 330 Ironman participants,72 reported a
significant increase in SCr in the participants using an
NSAID. In contrast, a prospective ultramarathon study
Dumke et al69 studied a group taking an NSAID
(n=29) and a group not (n=25) with no significant
difference in SCr between groups.
Studies on collapsed runners
Two studies specifically reported on SCr levels in
runners who had collapsed.51 61 In the first, 36
collapsed runners had mean postrace SCr of 141
(±26) vs 123 (±23) mmol/L in a control group of 60
runners (p<0.01).51 Within 24 hours, mean SCr had
fallen to 104 (±13) mmol/L compared with 95 (±13)
mmol/L in the control group (p<0.05). Irving et al
included eight ultra-marathon runners who had
collapsed with hyponatraemia (<130mmol/L)
requiring hospital admission. Their postrace mean SCr
level was 89 mmol/L vs 104 mmol/L in a control group
(n=18). A repeat test on ‘recovery’ showed mean SCr
levels had reduced to 68 mmol/L (p<0.05) and 78
mmol/L (p<0.01), respectively.61
Other markers of possible renal dysfunction
The SCr provides the basis by which chronic kidney
disease (CKD) is defined, with the eGFR allowing strat-
ification of patients with CKD. However, the use of
SCr, and derived eGFR equations implies that creati-
nine production rate is at a steady state and hence, more
accurately reflects the GFR. This is not the case in
many acute clinical scenarios and clearly not during
and after, extreme exercise. The use of other candidate
molecules as potential markers of renal dysfunction is
emerging as a potential avenue to investigate the true
significance of endurance events on renal function—
particularly in the higher-risk group of participants
who have collapsed. Any potentially useful candidate
AKI biomarker(s) should ideally fulfil several criteria.
These include, the provision of information above that
currently available in determining abnormal renal
function and also distinguish prerenal azotaemia from
intrinsic renal disease. This is of particular relevance in
extreme exercise where a prerenal component may
predominate. If biomarkers could aid prognostication
regarding potential renal recovery this also would be
beneficial. Most recently identified biomarkers of AKI
can be broadly classified into three groups: low molec-
ular weight proteins which undergo glomerular
filtration and hence reflect glomerular function, or
markers of tubule damage, such as enzymes releasedT
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into the urine after tubular cell injury, or inflammatory
mediators either released by renal cells, or by infil-
trating inflammatory cells.
Cystatin C is an effective biomarker of glomerular
filtration, correlates well with GFR and is independent
of muscle mass.79 Indeed, studies on renal function
following strenuous exercise demonstrated that the
mean cystatin C rise was half that of the mean SCr rise
in runners following a marathon.54 Further studies
demonstrated a correlation between cystatin C and SCr
rise immediately after a marathon, with 40% of partici-
pants reaching the creatinine criteria for stage 1 AKI.55
Participants also demonstrated a rise in urinary neutro-
phil gelatinase-associated lipocalin (NGAL) and
urinary kidney injury molecule-1 (KIM-1), suggesting
early tubular dysfunction, although all biomarkers
returned to baseline within 24 hours. Hewing59 in a
Berlin marathon study (n=167), found cystatin-based
GFR was significantly decreased by RIFLE criteria, with
30% demonstrating a decrease of >25% (risk) and 8%
a decrease >50% (injury). All parameters returned to
baseline ranges within a 2-week follow-up period.
NGAL is a 25 kDa acute phase protein largely
produced by the kidney tubule, though it is also upre-
gulated in other pathological conditions. In a study of
16 ultramarathon runners62 mean increase in SCr was
38%, with a significant increase in serum NGAL,
urinary NGAL, as well as the urinary NGAL/creatinine
ratio. Other studies have demonstrated increases in the
urine protein:creatinine ratio 6–18 hours postrace.57 In
a study on 152 runners in a 161 km ultramarathon,
34% met AKI criteria, with those demonstrating more
significant degrees of injury having a significantly
higher CK concentration. In addition, urinalysis tests
that were positive for at least 1+ protein, 3+ blood
and specific gravity 1.025 predicted those meeting
the injury criteria with high sensitivity. The authors
commented that using this simple test could be a
useful screening test to identify those at highest rise.63
The diagnostic utility of most of the biomarkers
described to date to diagnose AKI prior to elevations
in SCr is variable. This is due, in part, to clinical
studies being hampered by diverse patient populations
with differing comorbidities, the timing of the meas-
urements and chosen cut-off values. More recently,
studies have emerged using two biomarkers associated
with cell cycle arrest, namely insulin-like growth factor-
binding protein 7 and tissue inhibitor of metalloprotei-
nases-2 .80 81 The concentrations of these two proteins
was found to be in the urine of patients at high risk of
AKI from a variety of aetiologies. Initial studies seem
to suggest that these perform better than other known
markers within this patient cohort; the mechanism of
which may be an ‘alarm signal’ raised by the renal
tubules, in response to stress. Furthermore, recent data
imply that the presence of these biomarkers in the
context of AKI may predict a worse prognosis in the
critically ill, so perhaps they may be able to identify aT
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group of athletes who may require closer follow-up (see
figure 1 for a pathway outlining the aetiology of endur-
ance exercise related renal dysfunction and potential
utility of a biomarker to risk stratify participants).82
DISCUSSION
Pathophysiological effects of exercise on renal function
Increased blood flow to the muscles during exercise is
accompanied by decreased renal blood flow propor-
tional to extent and duration of the physical effort.83
In moderate exercise, renal blood flow may fall to 25%
of the resting value, although GFR is preserved
through an increase in the filtration fraction, which
may double, limiting the transfer of metabolites or
substances through the glomeruli and reducing the
extent of exercise proteinuria.84–88 Extreme exercise
however, may decrease GFR by up to 50%, through
increased release of catecholamines, AVP and activa-
tion of the renin-angiotensin-aldosterone system.89–91
Whether prolonged reduction of renal blood flow is
associated with intrinsic renal injury is uncertain and
the clarification of this issue to date has been limited
by the lack of a reliable biomarker. Despite evidence
that AKI may progress to CKD, of the reported cases
of AKI following an endurance event, we could find no
documented case of progression to CKD. From the
studies involving endurance events, SCr increases
significantly, although whether this represents a signifi-
cant insult to the kidney is not clear.
Extreme exercise—specific risk factors for AKI
Despite rises in measured SCr, the evidence for AKI
requiring medical intervention is sparse. However,
there are several conditions whereby the effects of
extreme exercise on the kidney can be exacerbated.
These include the development of pigment nephrop-
athy, the use of NSAIDs and exertional heat
stroke (EHS).
Pigment nephropathy
Rhabdomyolysis causes AKI through the direct toxic
effect of myoglobin on the renal tubule. Severe exer-
tion causes the syndrome through a combination of
mechanical and thermal muscle injuries. Both intensity
and duration of exercise are related to muscle damage
in a dose-response manner.92–94 CK is the most sensi-
tive marker of myocyte injury with levels at least five
times above the upper limit of normal required to fulfil
the diagnosis of rhabdomyolysis, although absolute
levels do not correlate well with disease severity, nor
risk of renal failure.95 96 AKI is common where rhab-
domyolysis complicates critical illness, whereas in
exercise-related rhabdomyolysis, AKI is rare. For
example, Skenderi et al,97 found markedly raised CK
levels in 39 runners after an ultra-marathon, yet none
required medical assistance, nor developed AKI. Rhab-
domyolysis with AKI has been observed following
exercise when extreme physical exertion has been
performed under conditions of high temperature,
dehydration with, or without acute illness.98 99
Non-steroidal anti-inflammatory drugs
NSAIDs inhibit cyclo-oxygenase, thereby preventing
prostaglandin synthesis (PGs). PGs enhance renal
perfusion through vascular dilatation and promote
diuresis and natriuresis through inhibition of sodium
transport in the thick ascending limb of loop of Henle
and the collecting ducts.100 101 PGE1 tends to antago-
nise the action of vasopressin and PGI2 in concert with
PGE2, serves to maintain the GFR.
102 103 In healthy
subjects, basal renal vasoconstrictor tone is low and the
vasodilation produced by PGs is not required for
normal renal function.104 105 In disease states however,
where increased sympathetic outflow to the kidney may
be found, PGs vasodilate the renal vascular bed and
ensure adequate renal blood supply. Therefore inhibi-
tion of PG synthesis may result in the unopposed
vasoconstrictive action of leukotrienes, angiotensin II,
vasopressin, endothelin and catecholamines. Indeed,
NSAIDs have been shown to decrease renal blood flow
with exercise, although this did not translate into
significant differences in GFR (measured by inulin
clearance) when subjects exercised at 80% VO2max for
30min.106 Olsen et al studied healthy volunteers under-
going submaximal exercise with and without
indomethicin.107 This NSAID significantly inhibited
renal PG synthesis and renin release. Overall renal
functional response to exercise remained unchanged,
possibly because of inhibition of renin-mediated angio-
tensin II generation and cyclo-oxygenase-1 mediated
thromboxane A2 synthesis.
Given that NSAIDs may have deleterious effects on
renal blood flow, does the use of these agents translate
into a higher risk of AKI in subjects undergoing
extreme exercise? To date, few studies have addressed
the impact of NSAID use on renal function after an
endurance event, compared with those not taking
NSAIDs. Reid et al found a significant mean increase in
creatinine in the NSAID group compared with those
not taking an NSAID in marathon runners.53 Wharam
et al72 in an Ironman study, reported a statistically
significant difference in SCr of 10 mmol/L among the
NSAID group, though this may not suggest a clinically
significant difference. In contrast, Dumke et al, in a
prospective study, found no significant difference in
markers of renal function between those who did, and
did not, use NSAIDs.69 However, our review data
presented here show that 18 of the 27 case reports
(67%) of renal failure (requiring hospital treatment)
following an endurance event had taken an NSAID,
which is in keeping with the widespread use of these
agents. With regard to pigment nephropathy,
conflicting results are found with studies showing an
increase, no effect or a decrease in markers of muscle
damage.108–110
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Exertional heat stroke
AKI is often found in patients with EHS, which can be
fatal.111–114 In addition to rhabdomyolysis and volume
depletion, alterations in circulating vasoactive media-
tors are implicated.115 Subsequent multiorgan injury
results from a complex interplay between the cytotoxic
effect of the heat and the inflammatory and coagula-
tion responses of the host.116 There have been recent
guidelines developed to reduce the risk of EHS partic-
ularly in warm environments from the perspective of
the athlete (including heat acclimatisation, initiate
competition in an euhydrated state and minimise dehy-
dration) and event organisers (provide shaded areas,
cooling and rehydration facilities, and suitably schedule
events).117
Exercise-induced AKI developing after anaerobic exercise
Exercise-induced AKI developing after anaerobic exer-
cise (coined ALPE) is an uncommon syndrome
differing from rhabdomyolysis by normal or slightly
elevated serum muscle enzymes associated with muscle
damage and the presence of severe loin pain. Vasocon-
striction of intrarenal arteries within the kidney is
thought to be the cause and studies using CT demon-
strate multiple wedge-shaped areas of contrast
enhancement in keeping with patchy vasoconstriction
of the renal vessels. It is thought that vascular spasm
accounts for the pain reported.118–121 Interestingly, a
recent review of 118 cases of ALPE demonstrated a
high percentage of subjects had hypouricaemia which
can be associated with exercise-induced AKI.118
Limitations of the study
To the authors’ knowledge this is the first systematic
review to address case reports of AKI in association
with endurance events and provides evidence from a
number of observational studies, as to the effects of
endurance events on SCr. The studies included were
heterogenous (though most scored highly on a risk of
bias assessment) and none included a significant time
of follow-up, nor was any study found looking at the
effect of performing multiple endurance events, over a
period of years. Newer studies with renal biomarkers
have suggested an increased SCr may be due to more
than just an enhanced solute load and reduced clear-
ance. However, firm conclusions as yet cannot be
drawn from the available evidence. The case reports of
significant renal injury by their retrospective nature
have limitations, though the relatively large number
with similar histories (acute illness, collapse, nephro-
toxic drug use and delayed presentations) allows some
interesting information to be drawn.
Figure 1 Pathway outlining the aetiology of endurance exercise related renal dysfunction and potential utility of a biomarker
to risk stratify participants. *Chronic disease such as hypertension, diabetes, chronic kidney disease. NSAID, non-steroidal
anti-inflammatory drug.
Hodgson LE, et al. BMJ Open Sport Exerc Med 2017;3:e000093. doi:10.1136/bmjsem-2015-000093 11
Open Access
D
epartm
ent G
eorge Edwards Library. Protected by copyright.
 o
n
 O
ctober 24, 2019 at Periodicals
http://bmjopensem.bmj.com/
BM
J O
pen Sport Exerc M
ed: first published as 10.1136/bmjsem-2015-000093 on 14 June 2017. Downloaded from 
CONCLUSIONS
AKI requiring medical attention associated with
extreme exercise is rare, with only 27 cases identified
in this review, usually thought to be primarily due to
rhabdomyolysis. Most cases had a number of risk
factors for AKI, including the use of NSAIDs and an
intercurrent illness or gastrointestinal upset. The
majority presented in a delayed fashion, emphasising
the need for awareness of this rare complication,
particularly among participants who have become
unwell during an event. It is likely that less severe
cases of AKI with rhabdomyolysis go unreported and
self-resolve. In contrast, an SCr rise after a marathon
or ultra-marathon is common, with an average rise of
29 (±12.3) mmol/L, which appears to improve rapidly.
However, there are few studies of collapsed runners
with deranged renal function and their longer-term
follow-up. Furthermore, in light of gathering evidence
that strenuous exercise could have some adverse
effects, it is not clear whether repeated participation in
such events may eventually lead to significant long-
term renal dysfunction. New biomarkers may be able
to differentiate between an increased SCr due to an
enhanced solute load and reduced clearance, rather
than direct tubular damage. As such, their use in
collapsed runners, who represent a higher-risk group,
may be of future interest, as an addition to routine
point-of-care testing.
RECOMMENDATIONS
Below are our pragmatic recommendations:
1. All marathon runners (or other endurance runners)
should be given advice regarding the avoidance of
NSAIDs, monitoring of urine volume and colour
and the importance of adequate hydration.
2. Participants with pre-existing risk factors (for
example, pre-existing renal dysfunction, hyperten-
sion and diabetes) should be made aware of the
potential dangers of NSAIDs and systemic upset
(such as vomiting) around the time of the event.
3. Runners who have collapsed during or at the end of
a marathon, should have their observations recorded
and basic investigations performed (including a
urine dip and basic biochemistry); abnormal results
should be followed up within a suitable time frame,
according to local resources.
4. Future research could focus on biomarkers that
more specifically reflect renal dysfunction, to help
identify those at most risk and allow follow-up,
where dysfunction has been found.
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